VRTX · News · 20261103N

JOURNAVX Demand and Access

VERTEX PHARMACEUTICALS INC / MA · 2026-11-03 · Importance 20 · Surprise 24

A report characterized JOURNAVX pain-drug sales as light, indicating a slower-than-expected early commercial uptake. The report contrasted this with CASGEVY, which it described as having delivered a definitive beat. No sales figures, customer details, or geographic breakdown were provided.